Under-30s will be offered alternative to Astrazeneca over 'very rare' blood clot concern

Under-30s will be offered alternative to Astrazeneca over 'very rare' blood clot concern (Photo by GENYA SAVILOV/AFP via Getty Images)

The benefits of the Oxford/AstraZeneca vaccine continue to outweigh any risks for most people, the UK medicines watchdog has said, as European regulators ruled that unusual blood clots were "very rare side effects" of the jab.

A review by the European Medicines Agency's safety committee concluded on Wednesday that "unusual blood clots with low blood platelets should be listed as very rare side effects" of the Oxford/AstraZeneca vaccine.

Sign up to our public interest bulletins - get the latest news on the Coronavirus

Sign up to our public interest bulletins - get the latest news on the Coronavirus

Vaccination is extremely important’

Emer Cooke, executive director of EMA, said its review "confirmed that the benefits of the AstraZeneca vaccine in preventing Covid-19 overall outweigh the risk of side effects," adding: "Vaccination is extremely important in helping us in the fight against Covid-19."

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) said there were still huge benefits of the vaccine in preventing Covid-19 and serious disease.

However, due to a very small number of blood clots in younger people, those under the age of 30 will be offered Pfizer or Moderna instead.

Blood clots associated with the jab are very rare

Up to March 31, the MHRA has received 79 reports of blood clots accompanied by low blood platelet count, all in people who had their first dose of the vaccine.

Of these 79, a total of 19 people have died, although it has not been established what the cause was in every case.

The 79 cases occurred in 51 women and 28 men, aged from 18 to 79.

Of the 19 who died, three were under the age of 30, the MHRA said.

Some 14 cases of the 19 were cerebral venous sinus thrombosis (CVST), a specific type of clot that prevents blood from draining from the brain.

The other five cases were thrombosis.

Balance of risk

The MHRA has concluded that the balance of risk for the vaccine is "very favourable for older people" but more finely balanced for younger groups.

Prime Minister Boris Johnson said the Government believes the Oxford/AstraZeneca vaccine is "safe", telling reporters on a visit to Cornwall: "But the crucial thing for everybody is to listen to what the scientists, the medical experts have to say later on today."

He added on the vaccination programme: "You can really start to see some of the benefits of that - it's pretty clear that the decline in the number of deaths, the decline in the number of hospitalisations is being fuelled, is being assisted, the steepness of that decline is being helped by the rollout of the vaccines so it's very important for everybody to continue to get your second jab when you're asked to come forward for your turn."

More than 20 million doses of the AstraZeneca vaccine have now been given in the UK, saving an estimated 6,000 lives.